NEW YORK (Reuters Health)—Certolizumab pegol (Cimzia, UCB Pharma) in combination with methotrexate does better than methotrexate alone in certain patients with early rheumatoid arthritis (RA), according to one-year results from a new trial. As Dr. Paul Emery of the University of Leeds, UK, explains in an email to Reuters Health, “This study used a unique…
Search results for: Cimzia
Certolizumab Pegol Drug Studies Find No New Safety Issues
Plus, updates on clazakizumab, hydrocodone bitartrate extended-release capsules and other rheumatology drug news, safety information
Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
Plus, rheumatology drug news from EULAR 2014
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
The American College of Rheumatology Helps Keep Three Biologics Off the SAD List
In October, the Centers for Medicare and Medicaid Services directed carriers to again include three biologics in Medicare Part B coverage. (posted Nov. 19)
Drug Updates
Information on New Approvals and Medication Safety
Are We Playing It Safe?
Tumor necrosis factor alpha inhibition and the risk of solid malignancies
Drug Updates
Information on New Approvals and Medication Safety
REMS Required
How will this FDA drug safety program affect rheumatology offices?
Drug Updates
Information on New Approvals and Medication Safety